Lukas P. Frenzel
Koeln, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.
Journal: Antimicrobial agents and chemotherapy
Published: May 12, 2026
Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.
Journal: Haematologica
Published: April 20, 2026
Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantation.
Journal: Leukemia research
Published: January 09, 2026
Cancer-Associated BCL-2 Mutants Reveal Mechanisms Towards Venetoclax Resistance.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 09, 2025
Cancer-Associated BCL-2 Mutants Reveal Mechanisms Towards Venetoclax Resistance.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 09, 2025
Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia.
Journal: Hematology/oncology clinics of North America
Published: July 22, 2025
VINCENT: A randomized-controlled trial evaluating venetoclax plus azacitidine versus intensive chemotherapy in patients with newly diagnosed, NPM1-mutated AML.
Journal: Annals of hematology
Published: April 20, 2025
Post-transplant-cyclophosphamide plus everolimus as GvHD prophylaxis in refractory T- and B-cell lymphoma.
Journal: Bone marrow transplantation
Published: July 16, 2024
Post-transplant-cyclophosphamide and short-term Everolimus as graft-versus-host-prophylaxis in patients with relapsed/refractory lymphoma and myeloma-Final results of the phase II OCTET-EVER trial.
Journal: European journal of haematology
Published: December 31, 2023
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Journal: Nature communications
Published: October 23, 2023
Last Updated: 09/26/2026